Download - Research questions and design
![Page 1: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/1.jpg)
By:
Mahmoud Mahmoud, MD, PhD
Prof. of Clinical Pharmacology, JFOM, KSA
Prof. of Clinical Research, AUHS, CA
Developing an Idea for a Study & Formulation of a Research Question
![Page 2: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/2.jpg)
How
Why
Where
When
How much
Is it
Research question is the uncertainty Research question is the uncertainty in the population that investigator in the population that investigator
wants to resolvewants to resolve
So What?
![Page 3: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/3.jpg)
![Page 4: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/4.jpg)
Anatomy and Physiologyof Clinical Research
• Anatomy: what research is made of?
• Physiology: How it works ?
![Page 5: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/5.jpg)
Anatomy of Research• Research questions (primary & secondary)
• Significance (Rationale)
• Design: a- Observational
• 1- Cohort
• 2- Cross sectional
• 3- Case Control( Descriptive & Analytical)
(Prospective & Retrospective)
![Page 6: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/6.jpg)
b- Experimental (Interventional)• 1- Randomization
• 2- Blindness: Single blind, Double blind
• Subjects:1- Selections 2- Criteria
• VariablesMeasurements: 1- Predictable
2- Confounding
3- Outcome
![Page 7: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/7.jpg)
• Statistical issues:• 1- hypothesis
• 2- sample size
• 3- analytic approach
![Page 8: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/8.jpg)
Physiology of Research• To study the universe through people and
phenomena
• Addressing the correct questions
• Implementing the study (carry out)
• Error of Research:
![Page 9: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/9.jpg)
The scientific method
The scientific method is the best way to solve truth from lies and delusion.
1. Observe some aspect of the universe.
2. Invent a tentative description, called a hypothesis, that is consistent with what you have observed.
3. Use the hypothesis to make predictions.
4. Test those predictions by experiments or further observations and modify the hypothesis in the light of your results.
5. Repeat steps 3 and 4 until there are no discrepancies between theory and experiment and/or observation.
![Page 10: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/10.jpg)
Incredible Research Questions(Silly!!!)
• Who has more bacterial flora in the colon, men or women?
• What are the facial characteristics of faithful women ?
• Optimizing the sensory characteristics and acceptance of canned cat food: use of a human taste panel. (Journal of Animal Physiology and Animal Nutrition)
• Effects of cocaine on honeybee dance behavior. (Journal of Experimental Biology)
• Swearing as a response to pain. (NeuroReport)
• Pigeons can discriminate "good" and "bad" paintings by children. (Animal Cognition)
![Page 11: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/11.jpg)
How to develop a RQ ?
RQ develops from previous findings by investigator or others.
–Scholarship: Mastering literatures can serve as source background
–Mentors: are needed particularly for inexperience researcher.
![Page 12: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/12.jpg)
Primary and Secondary questions• Many studies have more than one research question.• Primary Question:
– Experiments often address the effect of intervention on several outcomes
• Secondary Questions:
– The advantages of having several questions:
Several answers can emerge from single study
– The disadvantages of having several questions:
This will increase the complexity of the design and implementation– More sophisticated statistical techniques are needed
![Page 13: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/13.jpg)
Being alert to new ideas and techniques
• Attend conferences
• A skeptical attitude– Not to believe what you see but try to find better
criteria
• New technology will be helpful for new insight and questions
• Teaching is an excellent source of inspiration
![Page 14: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/14.jpg)
Criteria of Good Research Questions
• F… I…N…E….R• Feasible
• Interesting
• Novel
• Ethical
• Relevant
![Page 15: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/15.jpg)
Feasible– To know the practical limits and problems of studying a
questions
• Adequate number of subjects, pilot survey is helpful
• Adequate technical expertise for recruitment measuring variables, analysis, putting questionnaire.. Etc. Using consultants or co-investigators can shape the research
• Affordable in time and money, this has to be known and evaluated early
• Manageable scope, big scope may not be feasible. Investigator need to narrow it
![Page 16: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/16.jpg)
Interesting– To the investigator
• Share this interest with consultant or outside expert before writing grant.
– To the funding Agent– To the company (pharmaceutical co)
![Page 17: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/17.jpg)
Novel– The aim is to find new information– Reiteration of previous research is not acceptable. – Novelty can be determined though literature review
or funding agent records• Confirm or refutes previous finding• Extends previous findings• Provide new findings
![Page 18: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/18.jpg)
Ethical– Good research must be ethically accepted. – Unacceptable risk or invasion of privacy is not
accepted– Institution Review Board (IRB) is essential for
consultation and approval
![Page 19: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/19.jpg)
Relevant– Imagine the various outcome and the possibility that
the outcome will add to:
• To scientific knowledge• To clinical and health policy• To future research directions
![Page 20: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/20.jpg)
Improving Research Question• An outline (1-2 pages) will be helpful for the
investigator to clarify the ideas about the plan.
• White paper or letter of understanding
• The outline will provide basis for colleagues to react to with specific suggestions
![Page 21: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/21.jpg)
Problems and SolutionsPotential ProblemPotential Problem SolutionsSolutions
A: The research question is not FINERA: The research question is not FINER
1.1. Not feasible:Not feasible:
* Too broad* Too broad - Specify a smaller set of variables- Specify a smaller set of variables- Narrow the question- Narrow the question
* Not enough * Not enough subjects availablesubjects available
- Expand the inclusive criteriaExpand the inclusive criteria- Eliminate or modify exclusion criteriaEliminate or modify exclusion criteria- Add other sources of subjectsAdd other sources of subjects- Lengthen the time frame for entry into studyLengthen the time frame for entry into study- Use strategies to decrease sample sizeUse strategies to decrease sample size
* Methods beyond * Methods beyond the skills of the the skills of the investigatorinvestigator
-Collaborate with colleagues who have the skillsCollaborate with colleagues who have the skills- consult experts and review the literature for consult experts and review the literature for alternative methodsalternative methods-Learn the skillsLearn the skills
![Page 22: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/22.jpg)
* Too expensive* Too expensive -Consider less cost study withConsider less cost study with * fewer subjects and measurements* fewer subjects and measurements * less expensive measurements* less expensive measurements * Fewer follow up visits* Fewer follow up visits
2- Not interesting, 2- Not interesting, novel or relevantnovel or relevant
-Consult a mentorConsult a mentor- Modify research questionModify research question
3- Uncertain ethical 3- Uncertain ethical suitabilitysuitability
-Consult with IRBConsult with IRB- Modify the research questionModify the research question
B- The study plan is vagueB- The study plan is vague
AmbiguityAmbiguity -Write the research question at an early Write the research question at an early stagestage- Get specific in the one to two pages Get specific in the one to two pages study planstudy plan . How subjects will be sampled. How subjects will be sampled . How variables will be measured. How variables will be measured
![Page 23: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/23.jpg)
Translational Research• Translation of findings from Ivory tower to
reality– T1: from lab to clinical studies (from Bench to
bedside)– T2: from clinical studies to health practice
(need process and collaborators)
T1 T2
Lab Research Population researchClinical Studies
![Page 24: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/24.jpg)
Hypothesis• Definition:
– It is a precise testable statement of what the researchers predict, it will be the outcome of the study.
• It is transformation of research questions into final and most specific version to establish the basis for tests of statistical significance.
• It summarizes the sample, design, the predictor and outcome variables
• This usually involves proposing a possible relationship between two variables: the independent variable (what the researcher changes) and the dependant variable (what the research measures).
![Page 25: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/25.jpg)
![Page 26: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/26.jpg)
Characteristics of a good hypothesis• Simple versus complex:
– One predictor and one outcome variable• Ex: Sedentary life style is associated with diabetes
– Combined predictor or outcome variable can be useful
• Specific versus Vague– To clarify subjects and the variables
• In advance versus after–the- fact– Hypothesis needs to be state before the study not after
reviewing the data.
– The after the fact leads to over interpretation
![Page 27: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/27.jpg)
Types of Hypothesis
• Null and alternative hypotheses
Null H (H0) There is no association between predictors and outcome
Alternative H (Ha): There is association between predictors and outcome
• One and two sided alternative hypotheses i.e.
One direction or 2 directions
![Page 28: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/28.jpg)
• If your prediction was correct, then you would (usually) reject the null hypothesis and accept the alternative. •If your original prediction was not supported in the data, then you will accept the null hypothesis and reject the alternative. •The logic of hypothesis testing is based on these two basic principles:
![Page 29: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/29.jpg)
• In research, there is a convention that the hypothesis is written in two forms:– the null hypothesis, or Hn, H0 and – the alternative hypothesis (called the experimental
hypothesis when the method of investigation is an experiment), or Ha or He (either shorthand version is acceptable).
• Briefly, the hypotheses can be expressed in the following ways:
– The Hn states that there is no relationship between the two variables being studied (one variable does not affect the other).
– The Ha states that there is a relationship between the two variables being studied (one variable has an effect on the other).
![Page 30: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/30.jpg)
• A research hypothesis (Ha) prediction is one that states that results are not due to chance and that they are significant in terms of supporting the idea being investigated.
• A 'null hypothesis' (Hn) prediction is one that states results are due to chance and are not significant in terms of supporting the idea being investigated.
![Page 31: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/31.jpg)
Types of Results
• The problem if results in the samples do not reflect the population– Positive– False positive (Type I)…… Need to be zero
• Alpha (reject the null hypothesis when it is actually true, level of statistical significance)
• Alpha of 0.05 or less– False negative (Type II)….Need to be zero
• Beta (failing to reject the null hypothesis, when it is actually false)
• Power (1-beta)– Negative
![Page 32: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/32.jpg)
![Page 33: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/33.jpg)
Type 1 Error: False Positive
• Claiming that two means are not equal when in fact they are equal. In other words, you
• reject a null hypothesis when it is TRUE.
Type 2 Error: False Negative
• Not finding a difference between two means when in fact there is a difference. In other words, you reject a null hypothesis when it is FALSE.
![Page 34: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/34.jpg)
• Avoiding of errors entirely is difficult but can be minimized by:– Increase sample size– Design – Different measurements
![Page 35: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/35.jpg)
• Strategy:• 1- Put a scale
• 2- Precision (reproducible) of observer, instruments and subject………. Repetition
• 3- Accuracy (confidence to measure reality)…….
Using gold standard
![Page 36: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/36.jpg)
![Page 37: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/37.jpg)
Designing Research
![Page 38: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/38.jpg)
I- Designing an Observational Study1- Cohort Study
• Powerful study
• Types: Descriptive, analytic, prospective and retrospective
• Prospective Study: structure, strength, weakness
• Retrospective study: structure, strength, weakness
![Page 39: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/39.jpg)
• Nested Case-control and case-cohort studies: structure, strength, weakness
• Multiple-cohort studies and external controls: structure, strength, weakness
• PLANNING A COHORT STUDY
![Page 40: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/40.jpg)
Prospective Retrospective Nested Case-control & Case cohort
Multiple-cohort & External
control
Structure Define samples And follow variable over Time for future outcome
Define samples and follow over time for outcomein the PAST
Nested case Control: is cohort study (P or R) then evaluate outcome occurrenceVs the controlCase-Cohort: Similar to NCC except no control casesare selected but random samples regardless of the outcome. Measurements can be used for the whole study samples
Different samples with different risk exposure.In occupational and environmental study.Registry and census are useful
Strength -Powerful -accurate measurements of variables in known outcome
-Powerful- Unbiased- Less costly-less time
-Useful for costly measurements-Unbiased
-For rare exposure and potential hazards
Weakness -Expensive-Inefficient in rare outcome -can’t evaluate pre-post disease
-Limited control-May not have information to answer the questions
- As cohort study-Baseline is affected by silent preclinical diseases-Storage of samples
-Retrospective study lacks the recorded
information
1-Cohort StudyDetermine Incidence of Disease
![Page 41: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/41.jpg)
2- Cross Sectional Study 3- Case Control Study
Structure - Select sample of population- Measure Predictor and outcome variableAll measurements are made at once.
- Select sample of population with disease- Select sample at risk free of disease- Measure predictor variablesGenerally Retrospective
Strength - Major source of health and habits information- Hypothesis determine cause and effect
- Determine prevalence of disease.- No waiting for outcome to occur (fast, inexpensive)- Examine network of causal links- Serial surveys used to determine the changes observed at several times
- Epidemiologically identify risk factors- Find strength between associated factors- Efficient for rare disease- Useful to generate hypothesis
Weakness - Difficult to establish causal relation- Does not fit for rare disease- Can not define the time duration of disease
- Increase risk of Bias- Can not measure prevalence or incidence- Limited information
![Page 42: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/42.jpg)
II- Designing Experimental Clinical Trial
A- Randomized Blind Clinical Trial
• Powerful design for causality
• Overcome: Bias, confounders
• Blinding is effective
![Page 43: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/43.jpg)
Steps
• 1- Selection of subjects
• 2- Measuring baseline variables
• 3- Randomize participants
• 4- Apply interventions (Placebo included)
• 5- Follow up Cohort
• 6- Measure outcome variables
• 7- Analyses of results
![Page 44: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/44.jpg)
Selection of Subjects• Inclusive Criteria:
• Optimize the rate of primary outcome
• Generalization with minimal high risk for feasibility
• Exclusive Criteria• Avoid unnecessary exclusions
• Exclude non-contributors to primary outcome. And who will be difficult to follow e.g. mental status, harmful, treatment is ineffective
• Reasonable guided by weighing
• Restrict recruitment
• Overcome the confounding variables
![Page 45: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/45.jpg)
• Sample size and recruitment strategy• Limited # of subjects is wasteful, unethical and
misleading conclusions.
• Design a trial with:• Large #
• Accessible population
• Enough time
• Enough money
![Page 46: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/46.jpg)
Baseline variables
• Collect tracking information (name, SS..)
• Demographic data
• Measure predictable variables (smoking)
• Measure outcome variable (ECG)
• Establish banks of materials
![Page 47: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/47.jpg)
Randomization
• In 2 or more groups (placebo included)
• Avoid Bias by correct randomization for treatment and groups
• Use Algorithm, blocked, stratified blocked to ensure no influence of the investigator.
• Separate team my be used
• IVRS (interactive voice response system)
![Page 48: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/48.jpg)
Applying Interventions
1- Placebo• Blinding is recommended to avoid:
1- Co-intervention
2- Biased assessment of outcome
• Blinding is difficult than randomization
• Unbinding and breaking the code must be available 24 hour (pharmacist is helpful)
• At end of the study ask subject and investigator for the guess
![Page 49: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/49.jpg)
2- Active Drug• It must be:
Effective, safe, highest tolerable dose
• Use a range of doses
• Choice of Control• Consider Co-intervention for ethical reasons
1- when patient is under regular medications
2- use statistical adjustment for difference between groups.
• Equivalence trial: under standard treatment.
![Page 50: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/50.jpg)
Follow up and Adherence to the Protocol
• Strategy for maximization:
1- Subject compliance
2- Easy intervention administration
3- Convenient visits
4- Painless study measurements
5- Encourage subject to be on trial
6- Find subject who lost follow up
![Page 51: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/51.jpg)
Measure outcome
• Clinical outcome Vs Surrogate outcome
• Statistical characteristics
• Number of outcome variables
• Valid outcome
• Adverse effect
![Page 52: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/52.jpg)
Staging of Testing New Therapy by FDA
• Pre-clinical• Phase I: Unblind, uncontrolled, few volunteers to test
safety
• Phase II: small, randomized, controlled, blinded to test tolerability, intensity, dose, pharmacokinetics
• Phase III: large, controlled, blinded to test effect and outcome
• Phase IV: large, observational (post marketing surveillance)
![Page 53: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/53.jpg)
TITLE: A prospective, randomized, open-label, multi-center, pharmacoeconomic evaluation, comparing XXX to epoetin alfa in patients with chronic kidney disease (CKD) stage V on dialysis.
INDICATION Anemia of chronic kidney disease
OBJECTIVES Primary:The primary objective of the study is to demonstrate significant provider time saving using XX monthly intravenous injections compared to up to three times weekly epoetin alfa injections for anemia management in in-center hemodialysis patients, while maintaining adequate Hb controlSecondary:Demonstrate safety of XX
TRIAL DESIGN Prospective, randomized, open-label, comparative, active-control multi-center study
![Page 54: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/54.jpg)
XX IV monthly
TARGET POPULATION Patients with chronic kidney disease (stage V) on dialysis treated with epoetin alfa for the treatment of CKD-associated anemia
LENGTH OF STUDY 9 monthsTitration period: 7 monthsEvaluation period: 2 months
INVESTIGATIONAL MEDICINAL PRODUCT(S)DOSE/ ROUTE/ REGIMEN
COMPARATOR “DRUG” (or STANDARD OF CARE)DOSE/ ROUTE/ REGIMEN
Epoetin alfa 1-3/week IV per dialysis center protocol
Epoetin alfaweekly dose
XXMonthly dose
<8000 IU 120 g/mL
8000-16000 IU 200 g/mL
>16000 IU 360 g/mL
![Page 55: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/55.jpg)
ASSESSMENTS OF:
- EFFICACY Co-Primary endpoints: Time and Motion and Hb change from baselineTime and motion will be average time spent on anemia treatment over months 7-9 after the first study dose.. The co-primary endpoint is defined as the change in Hb concentration from baseline to the average in months 7-9.
- SAFETY Safety endpoints:oVital signs (Pre- and post dialysis: BP, heart rate, body weight)oECGoAdverse eventsoLaboratory parametersoIron parameters: serum ferritin, serum iron, serum transferrin or total iron-binding capacity (TIBC); calculated transferrin saturation (TSAT) or percentage of hypochromic RBCsoHematology: hemoglobin (safety and efficacy), hematocrit, white blood cell count, platelet countoBlood chemistry: aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), alkaline phosphatase (ALP), albumin, C-reactive protein (CRP), glucose in non-diabetics, potassium, phosphorusoAnti-erythropoietin antibody determinationoDialysis adequacy: Kt/V or urea reduction ratio (URR)
![Page 56: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/56.jpg)
- INCLUSION CRITERIA
Age ≥ 18 Able to understand, provide and sign written informed consentCKD stage V on outpatient in-center hemodialysis therapyUnchanged mode of therapy for the last 3 months prior to entry into studyAnemia of CKD treated with epoetin alfa iv 3x/WAverage Hb 10-13 g/dL over last 3 months prior to randomization. No Hb values should be <10 or >13 g/dl during this period. Kt/V ≥ 1.2 or URR ≥ 65% Adequate iron status: Serum ferritin ≥ 100 ng/ml OR TSAT ≥ 20% (or percentage of hypochromic red cells < 10%). Iron supplement therapy, either iv or po is allowed.
![Page 57: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/57.jpg)
- EXCLUSION CRITERIA
Poor compliance with dialysis treatment, evidenced by >2 missed treatment monthly over the previous 3 months. Patients hospitalized during the previous 3 months prior to randomization for any cause except minor surgery such as vascular graft revision. Renal transplantEpoetin alfa dose >300 U/kg/week. Patients expected to change dialysis modality over the course of the studyImmunosuppressive therapy (other than corticosteroids for a chronic condition, cyclosporine and monoclonal/polyclonal antibodies) in the 6 months prior to enrollmentOvert gastrointestinal bleeding or any other bleeding episode necessitating transfusion within 3 months prior to enrollmentHemoglobinopathies (e.g., homozygous sickle cell disease, thalassemias of all typesHemolysisActive malignant disease (except non-melanoma skin cancer)
![Page 58: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/58.jpg)
- Chronic, uncontrolled or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)- Acute infection- C-reactive protein (CRP) > 30 mg/L- Temporary (untunneled) dialysis access catheter- Vitamin B12 deficiency- Folic acid deficiency- Uncontrolled or symptomatic secondary hyperparathyroidism- Poorly controlled hypertension (sitting pre-dialysis systolic blood pressure ≥ 170 mmHg – average of 2 screening values with at least one day between measurements)- History of seizures in previous 6 months prior to enrollment- Current (or history of) Pure Red Cell Aplasia- Platelets > 500x109/L- Chronic Congestive Heart Failure (NY Heart Association Class IV)- Myocardial infarction, severe or unstable angina, coronary artery disease, stroke, severe liver disease within the 12 weeks prior to enrollment- High likelihood of early withdrawal or interruption of the study for any reason
![Page 59: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/59.jpg)
- Surgery during the course of the study or within 30 days pre-randomization, unless simple surgery, i.e., simple dialysis access revision, laser photocoagulation, etc.,- Pregnancy or breast feeding- Women of childbearing potential without effective contraceptive methods- Previous treatment with XX- Administration of another investigational drug within 6 months prior to randomization- Administration of erythropoietin-related compounds other than those specified by this protocol within 6 months prior to randomization- Known hypersensitivity to any constituent of the study or reference medication- RBC transfusions within 3 months prior to randomization- Life expectancy <12 months from randomization. - Participation in studies testing investigational devices or dialysis solutions, unless reported to the sponsor in advance and approved by the sponsor.- Erythropoietin-related compounds other than those specified by this protocol within 6 months prior to randomization, during the screening/baseline or the treatment periods
![Page 60: Research questions and design](https://reader033.vdocuments.us/reader033/viewer/2022061116/54663eaeaf7959e5108b57cd/html5/thumbnails/60.jpg)